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Infective endocarditis (IE) remains a major medical 
concern because of its mortality and costs, and because 
its incidence is not decreasing [1,21. The prevention of 
this severe infection has long been considered desirable 
and possible; this has relied mainly on the administra- 
tion of antibiotics to cardiac patients at risk before they 
undergo a procedure considered to carry risk. How- 
ever, the indications for preventive treatment and the 
design of antibiotic regimens are not based on well- 
established scientific evidence, and recent studies have 
questioned the benefit of such treatment [3-6]. 
Recommendations for prophylaxis of IE have been 
established in most countries and regularly updated for 
more than 30 years, so they vary slightly from country 
to country 17-12], It is not the objective of this report 
to change national guidelines, but (1) to analyze 
comparatively the guidelines from seven different 
countries, namely France, Germany, the Netherlands, 
Scandinavia, Switzerland, the UK and the USA, and (2) 
to identify the points of agreement which can be the 
basis for uniform international recommendations, and 
those aspects which are still subjects of debate. 
Prophylactic antibiotics can be defined for certain 
conditions but (1) they cannot prevent every case of IE 
occurring in cardiac patients at risk or following 
procedures that carry risk, (2) they are distinct from 
antibiotic treatment of infectious episodes and foci of 
infection, which require rigorous treatment in cardiac 
patients at  risk, (3) they do not apply to prevention of 
early postsurgical IE, for which different antibiotic 
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regimens are required and which is excluded from this 
review, and, finally (4) antibiotic prophylaxis is only 
one aspect of the  general prevention of IE. 
The propositions presented below have been 
established through a group of international experts 
which was convened on 15 October 1992 to reach 
agreement on various topics concerning IE, among 
which was antibiotic prophylaxis. This group had two 
meetings and presented its conclusions for prophylaxis 
of IE at  the Meeting of the International Society for 
Chemotherapy, in Stockholm, Sweden, July 1993. 
The following report is an attempt to summarize the 
discussions. It first presents an analytic description 
of the recommendations from various countries, and 
second, a synthetic arialysis which comprise the pro- 
positions of the working group. 
COMPARATIVE ANALYSIS OF NATIONAL 
RECOMMENDATIONS 
Cardiac risk 
According to the different countries, the cardiac 
conditions predisposing to endocarditis which require 
antibiotic prophylaxis are very similar. Some countries 
have distinguished between the cardiac diseases at risk 
and those which are not at risk. Some countries have 
identified a subgroup of cardiac diseases which x e  
considered to carry high risk among the cardiac diseases 
at risk. This estiniation of the relative risk of IE 
according to the cardiac condition is based on limited 
scientific data. Thus, from country to country, the 
antibiotic regimen recommended for a given procedurr 
“The group of experts comprised: Al Halees, W.G. Daniel, 
D. Durack, P. Francioli, E. Gutschik, C. Leport, K. Ngu- 
Blackett, D. Stamboulian, J.T.M. Van der Meer, W.R. Wilson. 
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Table 1 Influence of the cardiac risk on the antibiotic schedules for prophylaxis of IE in different countries [7-121 
Trpe of procedure 
Dental Dental Gastrointeshnal 
(oral regimen) (parented or urologic 
regimen) 
France N o  No N o  
The Netherlands N o  No No 
Switzerland Yes Yes N o  
UK No Yes N o  
us No Yes No 
Germany Yes - Yes 
No  = same regimen in all cardiac patients at risk. 
Yes = different regimen for cardiac patients at risk and cardiac patients at high risk. 
may vary according to the supposed cardiac risk 
(Table 1). 
Table 2 Comparison of the national recommendations for 
prophylaxis of IE: oral prophylaxis, dental care (7-121 
Procedures at risk 
The risk of IE associated with various procedures has 
not been assessed in prospective studies until recently. 
Most of the recommendations rely on anecdotal clinical 
reports and data from experimental models [13-171. 
Most dental procedures are considered to confer risk; 
in some countries, prophylaxis is limited to procedures 
resulting in gingival or mucosal bleeding. Concerning 
non-dental procedures, several procedures in the 
oropharynx and upper respiratory tract are supposed to 
be covered with antibiotics. There are controversies 
concerning flexible bronchoscopy with or without 
biopsy, considered to be associated with risk in France 
and in Switzerland (for high-risk cardiac patients) and 
not in The Netherlands, the UK and the USA. Surgery 
on the digestive and urinary tracts is considered to be 
a risk in most countries. In some countries, coloscopy 
with biopsy is considered for prophylaxis only in high- 
risk patients. There is a similar debate concerning 
vaginal hysterectomy, vaginal delivery or fitting of an 
intrauterine device. There is also an extensive debate 
concerning transesophageal echocardiography. 
Antibiotic schedules 
Oral prophylaxis for dental and upper respiratory tract 
procedures (Table 2) 
The regimen consists of amoxycillin 3 g given orally 
1 h before the procedure in most countries. In some 
countries, oral penicillin is an alternative. A second or 
several additional doses of amoxycillin are recom- 
mended in some countries, especially for high-risk 
patients. In some countries this oral regimen is also 
used for some gastrointestinal procedures, in low-risk 
patients. For patients allergic to p-lactams, clindamycin 
is the most common recommendation, the dose 
Patients not allergic to penicillin 
Common to all 
France 
Germany 
The Netherlands 
Scandinavia 
Switzerland 
UK 
USA 
Patients allergic to penicillin 
Common to all 
France 
Germany 
The Netherlands 
Scandinavia 
Switzerland 
UK 
USA 
Amoxycillin 3 g 1 k b e f r e  
N o  second dose 
Penictllin 2 million units’ 
No second dose 
No second dose 
+ 750 mgx7 (if high risk) 
No second dose 
+ 1.5 g, 6 h later 
Clindamycin 1 h b e f r e  
600 mg 
or pristinamycin 1 g 
600 mg 
Erythromycinh 1 g + 500 mg X 3 
300-600 nig 
600 mg + 300 nig x 7 (if high risk) 
600 mg 
300 mg f 150 mg, 6 hours later 
or erythromycin 1 g stearate 
or 800 mg succinate 
+ 500 mg (400 mg) 6 h later 
a Instead of amoxycillin. 
Instead of clindamycin. 
varying from 300 to 400 mg. Alternative antibiotics, 
erythromycin or pristinamycin, are proposed in other 
countries. 
Parenteral prophylaxis for dental and upper respiratory tract 
procedures (Table 3)  
The common regimen is based on ampicillin or 
amoxycillin given as an intravenous infusion 1 h before 
the procedure, completed with a second oral dose 6 h 
later. There are differences in the dosages of ampicihn 
used in the different countries. Aminoglycosides are 
not added in some countries, while they are 
recommended in others, especially in high-risk 
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Table 3 Comparison of the national recommendations for 
prophylaxis of IE: Parenteral prophylaxis; dental care 17-12] 
~~~ 
Patients not allergic to penicillin 
Common to all 
Fraiice 
Gerinanv 
The Netherlands 
Scandinavia 
Switzerland 
UK 
USA 
Patients allergic to penicillin 
Commorr tu all 
France 
Germany 
The  Netherlands 
Scandinavi~ 
Switzerland 
UK 
USA 
A moxycillirr-~4 mpidl i r i  
Ik' infiisiori 1 k before 
+ otie oral second dose 6 h lafer 
2 g + 1 g orally, 6 h later 
Penicillin G 2M" 
t gentainicin 80 iiig or 
streptomycin 0.5 g IM or IV 
Bicillin 1 .2Ma 
2 g + gentamicin 2-3 mg/kg 
1 g + 1 g IV X 5 doses or 750 mg 
orally x 7 doses" 
+ gentainicin 120 nig + 80 ing 
X 5 doses IM or IVb 
1 g + 0.5 g orally, 6 h later 
+ gentamicin 120 nig I M  or IV 
2 g + 1 g orally, 6 h later 
+ gentaniicin 80 mg I M  or IVh 
I.iirtctirny~irr 1 g 
I I' 1-2 Ii ir!fi&m 
O r  teicoplaniri 400 mg IV bolus 
Erythroinycin 500 mg 
IV + 500 nig IV 6 h later 
- 
+ 1 g x 3 dosesh 
+ pentai~ucin~ 120 iiig + $0 nig 
X 5 doses IM or  IV 
+ geiicainicin 120 iiig IM o r  IV 
- 
,'Instead of arnoxycillin. 
'If high-risk patient. 
patients. For allergic patients, vancomycin 1 g as an 
intravenous infusion is proposed. Teicoplanin, which 
can be given as a 400-mg intravenous bolus, o r  
intravenous clindamycin are possible alternatives to 
vancomycin in some countries. 
Gastrointestinal and urologic procedures (Table 4) 
In general, parenteral prophylaxis is recommended. 
However, in some countries, low-risk patients may be 
given oral antibiotics. T h e  antibiotic regimens are 
tiniilar to those used for parenteral prophylaxis of dental 
procedures, except that an aminoglycoside is added in 
all countries in  order to have maximal activity against 
enterococci, and clindamycin is not suitable because it 
is not suficiently active against fecal streptococci. 
SYNTHETIC ANALYSIS-PROPOSALS OF THE 
GROUP OF EXPERTS 
Cardiac risk 
The risk of bacterial seeding on carduc valves remains 
Table 4 Comparison of the national reconlmendations for 
prophylaxis of IE: parenteral prophylaxis, gastrointestinal 
and urologic procedures 17-12] 
Patients not allergic to penicillin 
Common to all 
France 
Germany 
The Netherlands 
Scandinavia 
Switzerland 
UK 
USA 
Patients allergic to penicillin 
Comwion to 011 
France 
Germany 
The Netherlands 
Scandinavia 
Switzei-land 
UK 
USA 
.4rnuxycillir~-ilripi~illin 
II' i&siou I h befnrr 
t orre oral jtacond doxe 6 h later 
+ gentannciii IM or IV 
Ainoxycillin 2 g + 1 g orally, 6 h later 
+ gentamicin I .5 mg/kg 
Anipicillin 2 g' 
+ gentamicin 80 mg 
Ainpicillin 1 g + lg orally, 6 h later 
+ gentamicin 1.5 mg/kg 
+ 1.5 mgikg 6 h later 
Anipicilhn 2 g + pentarnicin 
2-3 nigikg" 
Anioxycdin 1 g + l g  IV X 5 dosesh 
or 750 nig orally X 7 doses" 
+ gentaniicin 120 nig + 80 iiig 
X 5 doses" 
Ainoxycillin 1 g + 0.5 g orally, 
6 h later 
+ gentaitucin 120 nig 
Ampicillin 2 g + 1.5 g orally, 
(I h later 
+ gentainicin 80 iiig 
Ihcomyrrrr J 2 
IV 1-2 Ii ir!fusion 
+ p r a n i i r i i i  I M  or IV 
or teicoplanin 300-1iig IV bolus 
+ gentamicin 1 . j  mg/kg 
Erythroiiiyciii 500 mg IV 
+ 500 mg IV 6 h later 
+ gentaniicin 1.5 mg/kg 
+ 1 ..5 mg/kg 6 h later 
+ gentaniicin 2-3 ingikg 
+ l g  X 3 doses" 
+ gentaniicin 120 ing + 80 mg 
x 5 dosesh 
or teicoplanin 4OO-ing IV bolus 
+ gentaiiiicin 120 iiig 
+ 1 p IV infusion, 8 h later" 
+ gentaniicin 8(1 mg t 80 ing, 8 h 
later" 
- 
,' No second dose. 
I' If  high-risk patient 
difficult to assess, since rigorous epidemiologic data are 
limited. Only patients with a prosthetic valve constitute 
a well-defined population at risk 118-201. In these 
patients, as in patients with previous endocarditis, the 
risk seems approximately 5-10 times higher than in 
patients with native valve disease. T h e  other cardiac 
diseases at risk are listed in  Table 5. T h e  risk associated 
with pure mitral stenotis is mild to moderate. I t  is 
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Table 5 Cardiac conditions at  risk requiring antibiotic 
prophylaxis for IE-International Consensus 
Cardiac diseases with the highest risk 
Prosthetic valves 
Congenital heart dnease causing cyanosis 
Previous IE 
Other cardiac diseases at risk 
Valvular heart disease”: AR, MR, AS, including MVP with 
Congenital heart disease which does not cause cyanosis, 
Hypertrophic obstructive cardiomyopathy 
MR,  and bicuspid aortic valve 
except IAC 
~ 
AR, aortic regurgitation; MR,  mitral regurgitation; AS, aortic 
stenosis; MVP, mitral valve prolapse; IAC, interatrial 
communication. 
a The risk associated with pure mitral stenosis is debated. 
Table 6 Cardac diseases not at risk for IE-International 
Consensus 
~ ~~ ~~ ~ 
IAC 
MVP without MR,  functional MI, mitral ring calcifications 
Coronary artery bypass grafting 
Cardiac pacemakers 
Implantable defibrillators 
Corrected left-to-right shunts 
IAC, interatrial communication; MVP. mitral valve prolapse; 
MR, mitral regurgitation; MI, mitral insufficiency 
suggested that a single antibiotic regimen be scheduled 
for all cardiac patients at risk, with a flexible 
formulation allowing the optimal regimen to be highly 
recommended for the patients with the highest risk. 
Furthermore, it appears worthwhile establishing the list 
of cardiac conditions which are not associated with risk 
of IE and do not require specific prophylaxis (Table 6). 
Procedures at risk 
It is widely accepted that dental procedures are the 
niain risk factors for IE [6] and should all be covered 
with antibiotic prophylaxis, with the only exceptions 
being procedures without any risk of bleeding, such as 
superficial caries and bloodless supragingival prosthetic 
preparations. Application of a local antiseptic is 
recommended, as an adjunct to antibiotic prophylaxis. 
It must be recalled that regular dental care is mandatory 
in all patients at risk. Apart from the mouth, it is 
difficult to identify with any accuracy the procedures 
which carry a risk of infective endocarditis and to 
quantiEj this risk. The procedures considered to carry 
risk are those responsible for bactereniia with a 
consistent frequency: however, it does not necessarily 
predict the risk of IE [21]. The duration of the 
procedure is a possible factor which has to be con- 
Table 7 Procedures at risk for IE requiring antibiotic 
prophylaxis-International Consensus 
~ ~~ 
Dental All procedures 
Upper respiratory tract Tonsillectomy-adenoidectomy 
Gastrointestinal Esophageal dilatation or surgery 
Endoesophageal laser procedures 
Sclerosing procedures of esophageal 
varices 
Abdominal surgery 
Urologic Instrumental procedures involving 
the ureter or the kidney 
Biopsy or surgery of prostate or 
urinary tract 
Procedures fur which the risk uf infective endocarditis is mntruversial 
Upper respiratory tract Fiberoptic fibroscopy 
Endotracheal tube inserhon 
Coloscopy with or without biopsy Gastrointestinal 
Genital Vaginal hysterectomy, vaginal 
deliveryd 
However, antibiotic treatment is required in cases of concomitant 
infection. 
sidered. Some procedures are supposed to be covered 
in all countries (Table 7). It is especially important to 
underline that negative urine culture should be 
obtained before urologic procedures. Gyneco-obstetric 
procedures are not in general, considered to be at risk 
[22]. Fitting ofan intrauterine device is not encouraged 
in cardiac women at risk, except in developing 
countries, where the risk of pregnancy should be 
weighed against the risk of IE. Also, patients under- 
going transesophageal echocardiography should not be 
given antibiotic prophylaxis [23] .  Although, for contro- 
versial procedures, no consensual recommendation can 
be made for routine use, in particular situations one 
practitioner may wish to give a patient some antibiotics. 
Antibiotic prophylaxis should be directed against 
viridans streptococci of the oropharyngeal flora in 
procedures involving the oropharynx and upper 
respiratory tract, and against enterococci of the diges- 
tive flora for gastrointestinal and urologic procedures. 
Antibiotic regimens 
In general, antibiotics for dental and upper respiratory 
tract procedures are given to prevent IE caused by 
viridans streptococci, which are usually highly suscept- 
ible to penicillin, while antibiotics for gastrointestinal 
and urologic procedures are given to prevent IE caused 
by enterococci which are less susceptible to penicillin. 
For dental and upper respiratory tract procedures, there 
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Table 8 Antibiotic prophylaxis for IE-International Consensus 
1 h before the procedure 6 h later 
d l i r i imu/  r q i r r r e r i  
No aIIergy to penicillin Aiiioxycilliii 3 g orally No  second doac 
Allergy to pcnicilliii Clindainyciii 300-600 ins orally No second dosc 
l;/1~.urb/e mod!ficafions.im mimmnl to maximal rqinirri 
Additional doses after the procedure 
Adjunctive use of aininoglvcosider 
Uie of parenteral route of adrninirtration 
Allcrgy to pcnicilliii 
Aiiioxycillin (aiiipicilliii) 2 g IV 
+ gentamicin 1.5 mg/kg IM or IV 
Vancomycin 1 g in 1-h IV infucion 
+ gmtainicin 1 .5 nig/kg IM or IV 
1-1.5 g orally 
1 s i n  I-h IV 
infusion” 
~ ~ 
Twelve hour, later instead of 6 h later 
are different reginiens for patients who can take oral 
medications, which is the most frequent situation, and 
for patients under general anesthesia, who require 
parenteral antibiotics. In all countries, antibiotic 
regimens are based on penicillins, and alternative 
regimens have been defined for patients who are 
allergic to penicillin. 
At the present time, comparison of the various 
national recommendations shows clearly that there are 
very slight differences from one country to another. It  
appears that the different regimens from the national 
guidelines vary within two limits. The minimal and 
siniplest regimen consists of a single oral dose of 
antibiotic. The maximal regimen relies on multiple 
doses and the synergistic and prolonged (multiple 
doses) effect of a cell wall-acting antibiotic and an 
aminoglycoside, and offers the widest margin of safety 
(Table 8). The antibiotic regimen for a given patient 
should be selected between these two limits. It can be 
proposed that criteria to select the appropriate regimen 
for a given patient should include the type of cardiac 
condition at risk, the type, number and duration of the 
procedure, and the conditions of anesthesia required to 
perform the procedure (Table 9). This presentation 
allows the antibiotic prophylaxis to be adapted to each 
individual situation. It  preserves the discretionary 
nature of the recommendations, the practitioner being 
responsible for his own patient in a given situation. 
CONCLUSIONS 
Antibiotic prophylaxis is recommended for cardiac 
patients at risk who undergo a procedure carrying risk 
1241. Present recoinmendations are close to the 
Table 9 Criteria to select the most appropriacc antibiotic 
regimen for proDhylaxis of IE-International Consensus 
Minimal regimen Maximal ~regiiiieii 
Cardiac risk High cardiac risk 
Dental procedure 
Single procedure Multiple procedure? 
Outpaticiits Hospitalized patient5 
Local anesthecia General anestheii 
Gactroiiitc~tinai or urologic procedure 
maximum that can be done and mininial additional 
benefits can be obtained by changing these guidelines. 
Attention has to be concentrated on patients and 
procedures with the highest risk, i.e. patients with 
prosthetic valves undergoing dental procedures [25,26]. 
Major efforts and research are needed to improve the 
compliance to the recommendations, which are usually 
made by the experts and used by practitioners and 
dentists. Diffusion of the information to the 
appropriate users, and assessment of the knowledge and 
application of the guidelines by dentists and patients, is 
required [27], 
Since this manuscript was validated by the whole 
panel, new US recommendations have been published 
1281 and discussed in the literature [29]. 
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